Esperion Therapeutics' (ESPR) Buy Rating Reiterated at Needham & Company LLC

Needham & Company LLC reiterated their buy rating on shares of Esperion Therapeutics (NASDAQ:ESPR - Free Report) in a report released on Tuesday, Benzinga reports. Needham & Company LLC currently has a $8.00 price target on the biopharmaceutical company's stock.

Separately, HC Wainwright reissued a buy rating and issued a $16.00 price target on shares of Esperion Therapeutics in a report on Monday, March 25th. Four research analysts have rated the stock with a hold rating and two have assigned a buy rating to the company. Based on data from MarketBeat, the stock currently has an average rating of Hold and an average price target of $9.33.

Esperion Therapeutics Stock Performance

ESPR stock traded up $0.25 during trading on Tuesday, reaching $2.37. 45,843,060 shares of the company traded hands, compared to its average volume of 6,964,175. Esperion Therapeutics has a 12 month low of $0.70 and a 12 month high of $3.40. The business has a 50 day simple moving average of $2.33 and a 200 day simple moving average of $2.06. The company has a market capitalization of $448.88 million, a price-to-earnings ratio of -1.12 and a beta of 0.89.

Esperion Therapeutics (NASDAQ:ESPR - Get Free Report) last issued its quarterly earnings data on Tuesday, February 27th. The biopharmaceutical company reported ($0.50) earnings per share for the quarter, beating analysts' consensus estimates of ($0.53) by $0.03. The company had revenue of $32.25 million for the quarter, compared to the consensus estimate of $26.84 million. During the same period in the previous year, the business earned ($0.76) EPS. As a group, research analysts forecast that Esperion Therapeutics will post -0.68 EPS for the current year.

Institutional Inflows and Outflows

Institutional investors have recently modified their holdings of the company. Connor Clark & Lunn Investment Management Ltd. raised its stake in shares of Esperion Therapeutics by 120.1% in the third quarter. Connor Clark & Lunn Investment Management Ltd. now owns 413,704 shares of the biopharmaceutical company's stock worth $405,000 after purchasing an additional 225,767 shares during the last quarter. GSA Capital Partners LLP raised its stake in shares of Esperion Therapeutics by 159.1% in the third quarter. GSA Capital Partners LLP now owns 1,116,655 shares of the biopharmaceutical company's stock worth $1,094,000 after purchasing an additional 685,733 shares during the last quarter. PSI Advisors LLC raised its stake in shares of Esperion Therapeutics by 161.5% in the fourth quarter. PSI Advisors LLC now owns 17,000 shares of the biopharmaceutical company's stock worth $51,000 after purchasing an additional 10,500 shares during the last quarter. SVB Wealth LLC purchased a new position in shares of Esperion Therapeutics in the fourth quarter worth about $181,000. Finally, Chicago Partners Investment Group LLC purchased a new position in shares of Esperion Therapeutics in the third quarter worth about $29,000. 47.39% of the stock is currently owned by hedge funds and other institutional investors.

About Esperion Therapeutics

Esperion Therapeutics, Inc, a pharmaceutical company, develops and commercializes medicines for the treatment of patients with elevated low density lipoprotein cholesterol (LDL-C). Its marketed products include NEXLETOL (bempedoic acid) and NEXLIZET (bempedoic acid and ezetimibe) tablets that are oral, once-daily, non-statin medicines for the treatment of primary hyperlipidemia in adults with heterozygous familial hypercholesterolemia or atherosclerotic cardiovascular disease who require additional lowering of LDL-C.